Travoprost ophthalmic - Ocular Therapeutix

Drug Profile

Travoprost ophthalmic - Ocular Therapeutix

Alternative Names: OTX TIC; OTX-TP; OTX-TP1; OTX-TP2; OTX-TPa; OTX-TPb; Sustained release travoprost

Latest Information Update: 10 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ocular Therapeutix
  • Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Glaucoma; Ocular hypertension

Most Recent Events

  • 08 May 2018 Ocular Therapeutix plans a one-year phase III safety extension study for OTX-TP (travoprost insert) for glaucoma in the second quarter 2018
  • 03 May 2018 Phase-I clinical trials of OTC-TIC in Ocular hypertension in USA (Ophthalmic)
  • 03 May 2018 Phase-I clinical trials of OTC-TIC in Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top